BTLA and B-cell chronic lymphocytic leukemia: Accordingly, herein, we provide the rationale for further investigating novel anti-BTLA mAbs such as icatolimab, and the clinical relevance of the BTLA/HVEM axis in CLL alone or in combination with BTK inhibitors.